Clinical trial · Observational
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Ibrance® Post-Marketing Database Study Incidence of Interstitial Lung Disease in Inoperable or Recurrent Breast Cancer Patients Treated With Palbociclib in a Post-marketing Setting: Cohort Study Using the Medical Data Vision (MDV) Database
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to: * compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the market) * look into the factors that can cause ILD in new users of palbociclib. This study uses patient data without giving out any personal information of the patient. This data is taken from a hospital-based claims database of the MDV database, that includes data from more than 400 hospitals in Japan. This study will use data of patients who are: * diagnosed with breast cancer that include newly treated with palbociclib and/or other endocrine-based therapies for inoperable or recurrent breast cancer between 25 November 2011 and 30 November 2024.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fulvestrant | Drug | Fulvestrant | ALIAS |
| palbociclib plus fulvestrant | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- New prescription of palbociclib with fulvestrant.
- description
- Patients treated with the combination of palbociclib and fulvestrant
- interventionNames
- Drug: palbociclib plus fulvestrant
- Drug: fulvestrant
- label
- New prescription of fulvestrant monotherapy before the launch of palbociclib
- description
- Patients treated with fulvestrant alone
- interventionNames
- Drug: fulvestrant
Primary outcomes (4)
- measure
- The hazard ratios of ILD in palbociclib plus fulvestrant to new users of fulvestrant alone
- timeFrame
- 25 November 2011 and 30 September 2024
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Having prescription records of drugs for endocrine therapy (aromatase inhibitors, SERDs, SERMs, and CDK4/6 inhibitors) from 25 November 2011 to 31 December 2024. * Having any breast cancer records with definitive diagnosis in the same month as the first prescription date. * Having any records in MDV database on or before 6 months prior to the first prescription date (\<= -180 days: first prescription date = 0 day). * Having any records in MDV database within 6 months prior to the first prescription date (-180 days to 0 day). Exclusion Criteria: * Having any records of anti-HER2 medication (e.g., trastuzumab, pertuzumab, lapatinib or trastuzumab emtansine) from 25 November 2011 to 31 December 2024. * Having any records of second primary cancer with definitive diagnosis
References
Publications (0)
Data not yet available